Annexon Biosciences is advancing its phase 3 program for geographic atrophy (GA) with a focus on preserving visual acuity in patients. The company anticipates a data readout in 2026, potentially bringing a new treatment option to individuals affected by this progressive form of vision loss.
Douglas Love, president and CEO of Annexon Biosciences, presented details of the program at Eyecelerator@AAO. According to Love, the primary endpoint of the phase 3 program is visual acuity, with the aim of slowing disease worsening and preserving patients' vision for an extended period.
Clinical Significance
Geographic atrophy is an advanced form of age-related macular degeneration (AMD) that leads to irreversible vision loss. Currently, treatment options are limited, highlighting the urgent need for effective therapies that can slow or halt disease progression. By focusing on visual acuity as the primary endpoint, Annexon's program directly addresses the most critical concern for patients with GA: maintaining their sight.
The phase 3 program's emphasis on visual acuity reflects a commitment to clinically meaningful outcomes. If successful, this approach could significantly improve the quality of life for individuals with GA by preserving their ability to perform daily tasks and maintain independence.
Anticipated Data Readout
The anticipated data readout in 2026 will be a crucial milestone for Annexon Biosciences and the broader GA community. Positive results could pave the way for regulatory approval and the introduction of a new treatment option that addresses the unmet needs of patients with geographic atrophy.
